Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. has entered into a license agreement with Haisco Pharmaceutical Group Co., Ltd. for exclusive ex-China rights to two clinical-stage compounds, NXP100 and NXP200. This strategic deal involves an upfront payment of $20 million, potential initial development milestones of up to $20 million, and up to an additional $1.4 billion in contingent payments based on future development, regulatory, and commercial milestones, plus tiered royalties. The agreement significantly expands Nuvectis' pipeline into complement-mediated diseases and enhances its oncology portfolio with potentially best-in-class assets.

Nuvectis Pharma announced a strategic portfolio expansion through a license agreement with Haisco Pharmaceutical Group for exclusive ex-China rights to two clinical-stage compounds, NXP100 and NXP200. This deal transforms Nuvectis into a late-stage clinical development company, expanding its pipeline into complement-mediated diseases and enhancing its oncology product offerings. Haisco will receive up to $40 million in upfront and near-term payments, with potential for up to $1.421 billion in additional development, regulatory, and commercial milestone payments, plus tiered royalties.

Nuvectis Pharma reported a net loss of $(6.05) million for the first quarter ended March 31, 2026, an increase from $(5.33) million in the prior year. Cash and cash equivalents decreased to $25.1 million from $31.6 million at the end of 2025, with net cash used in operating activities rising to $(6.51) million. The company continues to advance its NXP900 clinical program, initiating the Phase 1b combination study in December 2025, but acknowledges the need for substantial additional capital to fund future operations and clinical trials.

Nuvectis Pharma reported a net loss of $6.1 million for the first quarter ended March 31, 2026, an increase from $5.3 million in the prior year period. Cash and cash equivalents stood at $25.1 million as of March 31, 2026, a decrease from $31.6 million at year-end 2025. The company highlighted continued patient enrollment in its NXP900 Phase 1b clinical program and presented preclinical data supporting NXP900's use in combination with sotorasib at the 2026 AACR Annual Meeting. A preliminary data readout from the NXP900 Phase 1b study is anticipated in summer 2026.

Nuvectis Pharma reported its first quarter 2026 financial results, with a net loss of $6.1 million, an increase from $5.3 million in the prior year. Cash and cash equivalents were $25.1 million as of March 31, 2026. The company continues to advance its NXP900 Phase 1b clinical program, actively enrolling patients in the US, and expects a preliminary data readout in the summer. Preclinical data supporting NXP900's use in non-small cell lung cancer was also presented at the AACR conference.

Nuvectis Pharma, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026. Stockholders will vote on the re-election of Ron Bentsur as a Class I director for a three-year term and the ratification of Kesselman & Kesselman as the independent registered public accounting firm for the year ending December 31, 2026. The record date for voting was April 13, 2026.